New drug, new hope: Roche tests Trontinemab potential to delay or prevent Alzheimer's
The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement.
Trontinemab is designed so that the drug is transported across the blood brain barrier – protective blood vessels that prevent chemicals in the bloodstream from entering the brain – in hopes of delivering more of the treatment to the brain.
Rivals like Eli Lilly have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the US.
Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
4 days ago
- The Sun
European drugmakers drop as Trump pushes for US price cuts
SINGAPORE: Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping executive order aimed at lowering prices. The letters were the latest setback for a sector still grappling with the prospect of tariffs outlined in the U.S.-EU trade deal that could cost the pharmaceutical industry between $13 billion and $19 billion. Trump called on 17 drugmakers to provide so-called most-favoured-nation prices to every patient enrolled in the government Medicaid health programme for low-income people, and to guarantee such pricing for new drugs. Shares of European drugmakers Sanofi, AstraZeneca , GSK, Merck KGaA and Novo Nordisk slipped between around 1% and 4% in early trading on Friday. Novo's 4% fall extends a selloff this week that started on Tuesday with a 28% plunge, wiping out $70 billion of its market value after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO. The companies were all sent letters by Trump, who gave them until September 29 to respond with binding commitments to those terms. U.S. drugmakers including Pfizer, Johnson & Johnson, Eli Lilly and Merck were also sent the letters. The European healthcare index was down 1.4% by 0731 GMT, its lowest since April. 'Trump's directive to the pharma companies will put them on the defensive and adds yet another layer of uncertainty for the sector which could also face import tariffs in time to come,' said Vasu Menon, managing director of investment strategy at OCBC. 'While Trump has set a deadline for these companies to comply, it remains to be seen if this is hard coded or if he will roll back some of his threats if these companies make an effort to engage him and soften his stance.' Analysts, lobbyists and drug pricing experts though said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. The companies including Pfizer, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Trump's executive order in May directed drugmakers to lower medicine prices to align with what other countries pay, leading to some shift in how drugmakers look to sell their medicines. Swiss drugmaker Roche said last week it was considering selling its prescription medicines in the United States directly to consumers to lower costs for patients as part of talks with the U.S. government. - Reuters
Borneo Post
6 days ago
- Borneo Post
SUPP man defends Deputy Premier Dr Sim's overseas engagements amid DAP criticism
Kua highlights ongoing discussions with Fudan University to establish a medical school branch in Sarawak, aimed at addressing the shortage of healthcare professionals, especially in rural areas. KUCHING (July 31): Political Secretary to the Sarawak Premier, Kua Jack Seng, has criticised Pending assemblywoman Violet Yong for her remarks against Deputy Premier Datuk Amar Dr Sim Kui Hian over his recent overseas engagements. In a strongly worded media statement, Kua, who is also the Sarawak United People's Party (SUPP) Engkilili Branch chairman, labelled Yong's remarks as 'misleading' and accused her of engaging in 'political hypocrisy'. 'These were not holiday jaunts but targeted, high-level engagements to explore and secure partnerships that could elevate Sarawak's healthcare landscape,' said Kua. He highlighted ongoing discussions with Fudan University to establish a medical school branch in Sarawak, aimed at addressing the shortage of healthcare professionals, especially in rural areas. Talks were also held with the US Centers for Disease Control and Prevention (CDC) to set up Malaysia's first CDC collaborative office in Sarawak. The initiative is intended to strengthen epidemic preparedness and public health surveillance. Additionally, engagements with Swiss pharmaceutical firms Roche and Novartis could pave the way for the state's first-in-human clinical research, positioning Sarawak as a future regional medical research hub. Kua also claimed that Democratic Action Party (DAP) leaders were 'opposing or downplaying' such efforts, thereby undermining Sarawak's healthcare progress. 'Why does DAP keep sabotaging Sarawak's move forward in healthcare?' he asked, defending Dr Sim's record of delivering rural health initiatives such as mobile clinics, flying doctor teams, digital health services, and the Health White Paper. He pointed out that over RM200 million in state funds had been allocated to upgrade healthcare facilities in remote districts such as Kapit, Lawas, and Limbang. Kua challenged DAP's 40 MPs to explain their lack of support for Sarawak's push for healthcare autonomy and questioned if they had done anything to secure better federal allocations. 'If federal healthcare delivery is failing, as Violet Yong herself admits, then what have DAP MPs done to fix it? 'Have they supported Sarawak's push for healthcare autonomy? Have they secured more federal health allocations for Sarawak? 'Have they ever tabled a motion in Parliament to reform the broken healthcare system they now criticise?' he asked. 'Sarawak needs builders, not noise-makers. Improving public health requires serious leadership, strategic engagement, and the courage to act, not just taking selfies or shouting in press releases,' he stressed. Kua concluded by calling on DAP members and Yong to focus on real solutions for rural Sarawakians rather than engaging in finger-pointing. 'If DAP and Violet Yong truly care about rural Sarawakians, they should stop sabotaging Sarawak's global partnerships and start doing their jobs in Parliament, like supporting Sarawak's rights under MA63, including the push for healthcare autonomy. 'Sarawak doesn't need more finger-pointing – it needs solutions and true leadership.' dap Dr Sim Kui Hian Kua Jack Seng lead overseas engagements
Malay Mail
7 days ago
- Malay Mail
New drug, new hope: Roche tests Trontinemab potential to delay or prevent Alzheimer's
BASEL, July 30 — Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier – protective blood vessels that prevent chemicals in the bloodstream from entering the brain – in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the US. Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
